Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:BCTXW

BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis

→ 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad)
Free BCTXW Stock Alerts
$0.59
+0.04 (+7.38%)
(As of 05/17/2024 08:53 PM ET)
Compare
Today's Range
$0.51
▼
$0.62
50-Day Range
$0.55
▼
$1.54
52-Week Range
$0.51
▼
$3.30
Volume
27,700 shs
Average Volume
29,331 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
BCTXW stock logo

About BriaCell Therapeutics Stock (NASDAQ:BCTXW)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTXW Stock Price History

BCTXW Stock News Headlines

May 16, 2024 | uk.investing.com
Briacell Therapeutics Corp (BCTX)
February 20, 2024 | finance.yahoo.com
Get Rich Quick With These 3 Penny Stocks to Buy Now
February 7, 2024 | finanznachrichten.de
BriaCell Therapeutics Corp.: BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
February 6, 2024 | finance.yahoo.com
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
January 6, 2024 | theglobeandmail.com
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
January 4, 2024 | finance.yahoo.com
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
December 6, 2023 | finance.yahoo.com
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
November 30, 2023 | finanznachrichten.de
BriaCell Therapeutics Corp.: BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor
November 30, 2023 | finance.yahoo.com
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
October 18, 2023 | finance.yahoo.com
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
October 4, 2023 | finance.yahoo.com
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
August 25, 2023 | finance.yahoo.com
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
May 25, 2023 | finance.yahoo.com
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
April 17, 2023 | finance.yahoo.com
BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR
April 3, 2023 | bizjournals.com
BriaCell intends to launch a spinoff to accelerate its drug development activities
March 15, 2023 | finance.yahoo.com
BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
January 23, 2023 | finanznachrichten.de
BriaCell Therapeutics Corp.: BriaCell to Investigate Alleged Illegal Trading of Public Securities
January 10, 2023 | finance.yahoo.com
BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
December 8, 2022 | finance.yahoo.com
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
October 21, 2022 | finance.yahoo.com
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
August 4, 2022 | finance.yahoo.com
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
June 29, 2022 | finance.yahoo.com
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BCTXW
CUSIP
N/A
CIK
1610820
Web
N/A
Phone
604-921-1810
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. William V. Williams M.D. (Age 69)
    CEO, President & Director
    Comp: $785.3k
  • Mr. Gadi Levin B.Com. (Age 51)
    C.A., CPA, M.B.A., CFO & Corporate Secretary
    Comp: $304.46k
  • Dr. Miguel A. Lopez-Lago Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $298.9k
  • Dr. Giuseppe Del Priore M.D. (Age 62)
    M.P.H., MPH, Chief Medical Officer
    Comp: $492.5k
  • Dr. Charles Louis Wiseman FACP (Age 78)
    M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board
    Comp: $241.14k

Key Competitors

View All Competitors

BCTXW Stock Analysis - Frequently Asked Questions

How have BCTXW shares performed in 2024?

BriaCell Therapeutics' stock was trading at $2.50 at the start of the year. Since then, BCTXW stock has decreased by 76.4% and is now trading at $0.5906.
View the best growth stocks for 2024 here.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCTXW) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Urgent Nvidia Warning
Altimetry
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders